Palladian’s Team Expands

We are delighted to announce three new additions to Palladian’s team, with Andrew Marchant joining us as an Investment Committee member and Vincenzo Barbiero and Aditya (Adi) Chugh joining the investment team.

Andrew Marchant has had a long and successful career in private equity. He initially worked for the Prudential before he became a founding partner of Permira. He was subsequently a director and shareholder in Cinven for 13 years where he initiated, led and managed buy out and growth capital investments.

He has since held a number of non executive roles including serving as Chairman of Unigestion's Private Equity division, Chairman of YFM Equity Partners and other senior advisory roles.

Vincenzo Barbiero joins us as a Vice President.

Prior to Palladian, Vincenzo’s roles included working at Progressio, an Italian mid-market private equity firm, and the M&A team at Intertek plc, a FTSE100 company and a global leader in the Testing, Inspection, and Certification sector, where he acquired and integrated companies across multiple geographies, with a particular focus on Europe, North and South America.

Adi Chugh joins us as an Associate. 

Prior to Palladian, Adi spent four years at Deutsche Bank, predominantly in the technology team in London with a focus on M&A transactions, leveraged buyouts and private placements. 

Doug Oppenheim and Sobhi Hatem, co-managing partners of Palladian, commented: 

“We are thrilled to have Andrew, Vincenzo and Adi join us. Andrew has many years of buy out experience and we are delighted to have him join Palladian’s investment committee. The addition of Vincenzo and Adi represents a significant expansion of our investment team, increasing both our new transaction capacity as well as the support we provide to our portfolio companies to help them to go further and faster.”

Intelli-Park expands National Footprint with acquisition of Bank Park

Intelli-Park, a prominent provider of parking technology and management services in the United Kingdom and Germany, has announced its acquisition of the regional operator Bank Park. 

Based in Sheffield, Bank Park is celebrated for its fair and ethical car parking solutions, serving a diverse client base, including landowners, agents, and retailers. Under this acquisition, Bank Park will retain its established brand name and Sheffield-based team, ensuring a seamless transition for its existing clients. 

This acquisition marks a significant step in Intelli-Park’s expansion strategy, broadening its reach into new regions while strengthening its network of client-focused, technology-driven parking solutions. The addition of Bank Park’s skilled team and customer service ethos aligns perfectly with Intelli-Park’s values, furthering both companies’ shared commitment to innovation and high service standards. 

For Intelli-Park, the acquisition underscores its mission to build future-ready sites across the nation, enhanced by its industry-leading technology and expansive client service network. With over 300 professionals, Intelli-Park currently manages more than 2,500 sites across various sectors, including residential, retail, healthcare, hospitality, and education. Its blue-chip clients include McDonald's, Savills, JLL, the NHS, and Cushman & Wakefield. 

The UK car park management industry, valued at approximately £1.2 billion, is evolving with smart solutions that streamline payment systems, reduce wait times, and enhance user experiences. Through data analytics, operators are improving space utilisation and making data-driven decisions to meet rising demands. 

Ben Cooke, Group CEO of Intelli-Park, commented, “We are thrilled with the acquisition of Bank Park. As one of the top regional car park management providers in the UK, Bank Park has a stellar reputation and offers innovative solutions that will enhance our national expansion. Together, we look forward to setting new standards in car park management both in the UK and internationally.” 

This acquisition represents a milestone in Intelli-Park’s ambitious growth journey, further cementing its position as a leader in the car parking management sector.

Sciensus names Christian Tucat as Chief Executive Officer

Sciensus, a leading pan European, life sciences business, providing patient access, engagement and insight solutions, is pleased to announce the appointment of Christian Tucat as Chief Executive Officer. Mr Tucat succeeds Darryn Gibson, who has led the organization for the past six years.

Mr Tucat brings 25 years of experience in the life sciences sector, primarily focusing on helping pharmaceutical companies deliver lifesaving drugs and therapies to patients. Prior to joining Sciensus, Mr Tucat held multiple senior roles at Syneos Health, including Chief Business Officer, President of Syneos One and President of Real-World Evidence Solutions. His career also includes leadership positions at INC Research, PRA International, Eli Lilly, and GlaxoSmithKline.

At Syneos, Mr Tucat built a market-leading real world evidence business and founded and led Syneos One, a leader in fully integrated asset development, designed to accelerate asset value and time to market. In his last role as Chief Business Officer, Mr Tucat led Syneos Health’s global growth strategy across Clinical, Medical Affairs and Commercial services.

Christian Tucat said: “I am thrilled to be joining the tremendously talented team at Sciensus and to have the opportunity to build on the success that has been achieved. Sciensus’ focus on helping patients achieve better healthcare outcomes, along with its strong partnerships with pharmaceutical, private medical insurers and healthcare provider organisations, creates a unique opportunity to leverage valuable insights and make a significant impact on patient care.

I look forward to working with the exceptional team of colleagues, the Board, patient advocacy groups, health care providers/NHS and pharma partners to shape this important next chapter, as we continue to put patients at the centre of what we do. A key focus will be to further develop Sciensus’ adherence and digital insight capabilities and expand its global reach.”

Peter Nicklin, Chairman of Sciensus said:  “Over the past six years Sciensus has transformed into a leading technology-driven life science services company serving our chronic, rare disease and cancer customers. I am delighted that Christian is joining Sciensus and have every confidence that under his leadership we will continue to build a world class company that improves patient health outcomes.”

Doug Oppenheim, Partner, at Palladian Investment Partners, commented: “I am delighted to welcome Christian as CEO. Christian brings tremendous global experience and energy to Sciensus as the company is expanding its capabilities to support more  patients to make the most of their medicines.

Sciensus accelerates its digital patient support capabilities through acquisition of Vinehealth

Palladian is pleased to announce that its portfolio company, Sciensus, has acquired Vinehealth, a ground-breaking patient app and physician support platform. 

Sciensus is a leading technology-enabled pharma services business managing the complex medicine needs of more than 250,000 chronic, rare and cancer patients in the UK and Europe. 

In recent years Sciensus has invested heavily to build an integrated portfolio of powerful patient engagement and real world evidence solutions to enhance patient connectivity and insight. Centred on the market-leading InTouch app, these tools support more personalised care and enhanced patient outcomes. Every day thousands of patients use InTouch to help manage their condition.

Founded by Rayna Patel, formerly an NHS physician and Georgina Kirby, a leading data scientist, Vinehealth has grown to become the top-rated cancer support app. It is underpinned by best-in-class technology trusted by patients, physicians, life science companies, and regulators, with support and approvals from the NHS, FDA, MHRA, and EU-MDR.

The Vinehealth app empowers cancer patients by enabling them to track, manage and understand their symptoms. The platform creates valuable connectivity with clinical stakeholders, generating actionable insights to optimise clinical decision making and treatment management. Vinehealth is driving significant improvements in patient outcomes and medicine performance, enabling physicians and life science companies to transform cancer services.

The addition of Vinehealth further expands Sciensus’s digital platform. Sciensus will accelerate Vinehealth’s expansion into new geographies and therapeutic areas beyond cancer to support patients worldwide.

Commenting on the announcement, Darryn Gibson, CEO of Sciensus, said: “Vinehealth presents a rare and exciting opportunity to acquire a fast-growing, highly innovative business, which is transforming cancer patient outcomes and will significantly strengthen our digital insight offerings. We look forward to welcoming Rayna, Georgina, and their team to Sciensus and working together to enable cancer patients to be even more engaged with their treatment.”

The founders of Vinehealth said: “This deal marks an important milestone for Vinehealth. Uniting with Sciensus will extend our reach to patients by leveraging their patient network, and relationships with all the leading pharmaceutical companies and healthcare practitioners. Together, we’re poised to enhance the patient experience and generate meaningful patient insights through best-in-class patient support programmes and rich longitudinal real-world data to drive advancements in chronic disease patient support.”

Palladian Backs MBO of Intelli-Park

Palladian Investment Partners LLP is pleased to announce it has backed the management team of Intelli-Park, a leading UK provider of parking technology and management services, in a buyout from its founder. The transaction is valued at over £120 million, inclusive of earn outs, and marks the second investment for Palladian.

Intelli-Park’s intelligent parking solutions help real estate owners to manage and optimise their car park sites. In recent years the company has undergone a digital transformation, offering its customers a tech-enabled tool kit of mobility services which offers greater insights, convenience and efficiency. Founded in 2004, today Intelli-Park’s 270+ employees manage over 2,000 sites across the UK, with blue-chip clients including McDonalds, Savills, JLL and Cushman & Wakefield. The company has recently expanded its operations into Germany. 

The buyout, in which Palladian has acquired a majority stake in Intelli-Park, sees the management team, led by co-CEOs Ben Cooke and Jeff Harrison, remain at the helm.

The backing from Palladian will enable Intelli-Park to further enhance its technology and service offering, accelerate the roll-out of EV charging infrastructure across its estate and undertake acquisitions in the UK and Europe. As part of this transaction Vecturis Equity GmbH, a German fund focused on mobility services, has acquired a minority stake in the business alongside Palladian.

Solano Partners acted as the exclusive financial advisor to Intelli-Park and its shareholders on the transaction.

Doug Oppenheim, a partner at Palladian, said: "In recent years Intelli-Park has achieved a well-earned position as an innovator at the forefront of the parking management market, providing its customers with the digital tools and services to operate their parking assets and enhance their own customers’ experience. We are thrilled to be collaborating with the management shareholders led by Ben Cooke and Jeff Harrison and look forward to supporting the team to continue Intelli-Park’s growth over the coming years."

Ben Cooke, Group Co-CEO, Intelli-Park, commented: "We are excited to be partnering with Palladian. This buyout will enable us to accelerate innovation and provide best-in-class technology solutions to our customers. Palladian’s long-term outlook and their experience in digital transformation, M&A and supporting businesses grow in Europe made them a natural choice for us as we look to the future."

Debt facilities to support the acquisition were provided by Pricoa.

Palladian was advised by Osborne Clarke and Paul Hastings (legal), Cortus Advisory (financial), EY (tax), KPMG (debt advisory) and GK Strategy (regulatory). Intelli-Park was advised by Solano Partners (financial advisory), Pinsent Masons (legal), PWC (financial) and CiL (market).

Palladian announces the appointment of Sobhi Hatem as Partner and the appointment of David Morrison and Hamish Mackenzie as Senior Partners

Palladian Investment Partners LLP is pleased to announce that Sobhi Hatem has joined in the role of Partner, assuming joint responsibility for managing Palladian alongside Doug Oppenheim. 

Sobhi has over 20 years of private equity and investment banking experience. Prior to joining Palladian in 2023, Sobhi was Managing Partner at Central Ridge Partners, a private equity firm focused on investing in sustainability. 

Prior to that, Sobhi was a Managing Director and member of the investment committee for the European private equity fund of TRG. 

Before joining TRG Sobhi was a Managing Director at CVCI, the private equity fund of Citigroup. Through his career he served on the board of over 10 companies including Pet Networks International, Amethyst Radiotherapy and Huvepharma. He started his career as a Director in the TMT team at Lehman Brothers. 

Sobhi is a graduate of HEC (France) and holds an engineering degree from McGill University.

In parallel to this appointment, Palladian co-founders David Morrison and Hamish Mackenzie are appointed to new roles as Senior Partners, serving on Palladian’s investment committee and providing strategic guidance and support to the business. 

Doug Oppenheim commented:

“I have known Sobhi for many years and am thrilled to welcome him to Palladian. Sobhi brings exceptional investment experience and a passion for working with entrepreneurs and management teams and building great companies. 

I am also pleased to announce David and Hamish’s appointment to their new roles as Senior Partners and know that Palladian will continue to benefit from their continued support and counsel in the years ahead.”

Healthcare at Home unveils new vision for the future and renames itself Sciensus

Palladian portfolio company Healthcare at Home has announced a major rebranding exercise, including changing its name to Sciensus. The new name reflects the company’s forward-thinking approach, which aims to harness new digital technology and patient insight to provide patients with more knowledge, more choice and greater convenience.

With a workforce of over 1,700, including more than 500 clinicians across the UK, Healthcare at Home supports in excess of 200,000 patients every year across 49 therapy areas and 450 chemotherapy regimes.

Established in 1992, they have worked in partnership with the NHS, private medical providers and pharmaceutical companies to bring patients the life-changing treatment they need, in the comfort and convenience of their own homes. The new Sciensus vision is to become a global leader in supporting each and every patient to make the most of their medicine – helping people do better, feel better and get better results, long term.

The business has evolved from a home healthcare provider into a leading pharma services company offering a range of services including:

• Complex Pharmacy Services, serving the medication needs of over 200,000 chronically ill patients in their home

• End to end solutions for Biotech companies seeking access to the fast-growing European Rare Disease market

• Privately funded home cancer treatment, from inhouse aseptic compounding to chemotherapy nursing

Using valuable insights Sciensus will be helping patients take more control of their health and their personal goals. It will be easier to get support from specialist nurses, therapists and clinicians, easier to manage visits and deliveries, and easier to find helpful, practical information any time patients choose.

Later this year, Sciensus will be launching a new range of secure, user-friendly digital tools, designed in collaboration with patients, to provide more opportunities for them to take control of their medication, understand more about their treatment and condition, and connect with other patients and online support communities.

Richard Blyth, Chief Customer Officer, says: “We’re proud to be evolving our company and building a stronger, more supported future for patients all over the UK and Europe. We’ll still be the same friendly, caring and highly trained team that patients have come to rely on, but we’re making some exciting changes to help us better connect with them in intuitive new ways, every day. By providing things like virtual patient consultations, secure access to patient communities, medication reminders and quick, easy access to information on their condition, we will offer patients greater knowledge, choice, convenience and connection than ever before.”

Palladian portfolio company Healthcare at Home announces high levels of patient satisfaction in its Annual Survey

With an unprecedented response to its annual patient survey, Healthcare at Home reports satisfaction ratings increasing across its services. This year the company received 8,375 responses – an 18 per cent response rate, which is almost double the rate received in 2018.

The survey ran from 16 March to 10 April. Despite many patients feeling anxious about Covid-19 during this time, at least 95 per cent of patients were extremely satisfied or satisfied with Healthcare at Home’s customer service, delivery service and clinical services. 93 per cent of patients also said they would be extremely likely or likely to recommend Healthcare at Home to others if they needed similar care or treatment.

When combined into a ‘net promoter’ score (an international measure for how many more people would pass on a positive view of a company versus  a negative view), Healthcare at Home’s score is in the same league as Amazon and other hugely trusted brands of the world.

While the results of this year’s survey are extremely positive, Healthcare at Home is now focusing on stepping up its service levels, moving even more patients from being ‘satisfied’ to being ‘extremely satisfied’. The significant investment underway in digital services will support the company in providing even greater levels of support to its patients, helping them to have their best day, every day.

Healthcare at Home appoints Peter Nicklin as Chairman of the Board

Palladian Investment Partners is pleased to announce the appointment of Peter Nicklin as Chairman of the Board of Healthcare at Home. Peter joined the board as a non executive director in September 2018.

With over 30 years’ operational management experience across a broad international healthcare landscape including pharmaceuticals, biologics, vaccines, medtech and healthcare services, Peter has contributed a wealth of experience to the Healthcare at Home Board. He has significant global experience in healthcare business development leadership. His previous roles include Corporate Vice President and EMEA President of Baxter International, Board Member of Bayer Healthcare AG and Western and Central Europe lead for Novartis.

Peter’s most recent leadership role was as CEO and Member of the Board of Amann Girrbach AG, the leading innovator in digital dental prosthetics, based in Koblach, Austria, which he held from 2018 to 2020. Additionally, he is Chairman of the Board of Versantis, a Swiss pharmaceutical company developing a new generation of medicines and diagnostics to revolutionize the care of patients with liver disease.

A Chartered Accountant by training, Peter began his career at PricewaterhouseCoopers, after earning a bachelor’s degree at the University of Lancaster.

Homeward bound: moving systemic anti-cancer therapy out of the hospital

Systemic anti-cancer therapy vastly improves outcomes for many cancer patients, but frequent hospital trips can be exhausting and stressful. Palladian portfolio company Healthcare at Home provides more a more patient centric alternative.

Cancer treatment has come a long way since mustard gas was first tried in the 1940s to treat lymphoma patients. Better treatments have emerged that have changed the outlook for those with the disease. Mortality rates have significantly decreased and are projected to fall a further 15 per cent between 2014 and 2035, according to Cancer Research UK.

But although modern-day hospital-administered systemic anti-cancer therapy (SACT) is a far cry from the primitive therapeutic agents spawned by deadly weapons, it can still be a stressful, time- consuming and exhausting experience for patients and their families.

James Casey from Huddersfield was devastated when, four years ago, he received a diagnosis of peritoneal mesothelioma, a form of cancer caused by asbestos, which affects the lining of the abdomen. As there are few doctors who specialise in this condition, Mr Casey was placed under the care of a consultant, based more than 100 miles away in Leicester. For greater comfort and convenience, the consultant recommended treatment outside hospital.

“I was so poorly in the early days after diagnosis that I might have refused to go to the hospital because I was feeling so ill. It made a massive difference for nurses to come to my home and carry out the treatment. And it meant my friends and family didn’t have to take time out to visit me in hospital,” recalls Mr Casey, whose clinical home care is arranged by Healthcare at Home, the UK’s leading provider of clinical services given outside of hospital. “Without a doubt, it is a fabulous option for patients.”

“The truth is that hospitals can be scary places sometimes,” says Professor Sir Jonathan Asbridge, Healthcare at Home’s chief clinical officer. Around 6,000 patients are treated for cancer at any one time by the company and 450 SACT regimens are supported.

Many of the most commonly diagnosed cancers have a ten-year survival rate of 50 per cent or more, according to Cancer Research UK, but the treatment journey can still induce complex emotions for the patient, including a feeling of losing control of their life.

“One breast cancer patient in her late-30s recently told me: ‘I haven’t missed a day of being here for when my kids come home from school’,” says Sir Jonathan. “She stays at home rather than driving 60 miles to have SACT in the hospital.”

At-home cancer treatment needs to be as unobtrusive as possible, he explains. It should fit around the person’s life.

“You cannot underestimate the additional convenience treatment in the home can bring to the patient. Having SACT in a hospital involves travel, finding a parking space and, when you arrive, having bloods taken and waiting for the medication to be compounded. Often this can lead to a patient attending a hospital for the whole day for treatment that may only take an hour or two,” says Sir Jonathan.

But Healthcare at Home clinicians visit the patient two days before the medication is given to carry out the necessary blood tests and patient assessments, and conduct a clinical pre- assessment. This ensures on the day of medication the patient isn’t waiting around. “We bring the cancer therapy straight to you. All the patient does is have the treatment for that period of time and then they can get on with their life,” he says.

Sir Jonathan, who is also president of the European Society for Person- Centred Healthcare, says patient choice must be the future of clinical care. There’s a growing body of evidence supporting clinical home care for various medical conditions.

One study found care at home was associated with a 38 per cent reduction in mortality at six months compared with hospital treatment. And home treatment may also reduce the risk of a cancer patient with a compromised immune system contracting an infection. As well as good clinical outcomes, there are financial benefits for medical insurers and private patients who elect to self-pay, as some cancer medications are VAT exempt when administered at home.

Some of Healthcare at Home’s other services, such as infusion care, provide advantages for the NHS too, as by enabling discharge as soon as patients are medically fit, this can free up beds. Clinical home care may also reduce unplanned hospital admissions and waiting times.

The benefits for hospitals and patients sound impressive, but can SACT at home really be safe for everyone? Sir Jonathan cautions that a thorough risk assessment must be undertaken first. However, he points out that many hospital-type services can be safely given at home with patients remaining under the care of the referring consultant at all times.

For NHS patients, guidance is always sought from the local hospital to ensure the treatment provided is consistent with their clinical protocols. All Healthcare at Home’s specialist cancer nurses are trained to either degree or masters level, or hold an NHS-accredited chemotherapy qualification. They all undergo annual SACT accreditation to ensure their knowledge and skills are up to standard. And all patients have 24/7 access to a team of cancer clinical nurse specialists who support them and their families throughout the pathway.

Healthcare at Home has recently invested in a major digitalisation programme which it hopes will put even more control in the hands of patients, so they can arrange appointments and track medication deliveries online. Sir Jonathan is optimistic about the future of cancer treatment and believes combining research breakthroughs and patient-centred care could make a huge difference to people’s lives, “enabling them to have their best day, every day”, he says.

Copyright Healthcare at Home 2020

Palladian portfolio company Healthcare at Home awarded “Good” CQC rating across all inspection criteria.

The nation’s leading Medicine Services provider, Healthcare at Home, has been rated GOOD by the Care Quality Commission following a recent inspection.

The service, which is the leading pan-European insight based Medicines Service for complex medicines, creates better outcomes for patients by ensuring greater treatment support.

With unparalleled expertise, which has been established through 25 years of in-depth knowledge of patient-medicine behaviour, Healthcare at Home has one million interactions with varied NHS and private patient populations.

Darryn Gibson, Healthcare at Home Chief Executive said: “We are very pleased with our overall ‘Good’ rating which The Care Quality Commission has given us following their inspection at the end of last year.

“Particularly pleasing was the consistency that the business demonstrated across all areas. A rating of GOOD was achieved in every one of the five domains inspected – Safe, Effective, Caring, Responsive and Well-led Services was achieved.

“The report highlights many of the ways in which our dedicated and hardworking teams are providing the best care for our patients, enabling them to have their best day, every day.

“Our main focus at Healthcare at Home is to ensure that we do everything we can to make sure our patients receive the highest level of safe and quality care.  We are investing more resource and capital into state-of-the-art digital healthcare to support and enable more patients to make the most of their treatment allowing them to have their best day, every day.

“This investment in technology will ensure that Healthcare at Home is easy to do business with today, and into the future, helping us to move confidently towards an ‘outstanding’ rating.”

With over 400 specialist nurses employed across the UK, a 24/7 patient advice line and a cold chain logistics operation, Healthcare at Home supports over 180,000 patients per year across 49 therapy areas and 450 chemotherapy regimes.

Healthcare at Home retains spot on Sunday Times HSBC Top Track 100. 

Palladian congratulates investee company Healthcare at Home in once again been featuring in the annual Sunday Times HSBC Top Track 100, retaining its position at number 30. The league table ranks Britain’s 100 private companies with the largest sales.

About Healthcare at Home

HAH is the UK’s leading in-home provider of managed medication services for high-cost medicines. The company has substantial expertise which has been established through in-depth knowledge of patient-medicine behaviour, in particular with biologic medicines.

Its 1,500-strong workforce, of which half are clinical roles, means HAH has the ability to manage varied patient populations, from small to large, at a fast pace while maintaining high standards.

Based in Burton upon Trent, it also has operational hubs in the Netherlands and Switzerland.